BUZZ-Revvity falls on forecasting 2025 revenue, profit below estimates

Shares of medical equipment maker Revvity RVTY.N fall 2.4% to $123.75

Co forecast 2025 profit and revenue below estimates

Co forecast 2025 adj. profit to be in the range of $4.90 to $5.00 per share, compared with analysts' estimates of $4.99, as per data compiled by LSEG

Forecast 2025 revenue to be in the range of $2.80 bln to $2.85 bln, lower than estimates of $2.87 bln

RVTY was expected to forecast lower with both Danaher DHR.N and Thermo Fisher TMO.N guiding lower vs. the Street expectations, brokerage Leerink Partners says

Adds, "thus we see limited downside surprise" as the outlook is still 4% organic growth at the midpoint, which is higher vs. peers so far

Co, however, beats Q4 profit and revenue estimates on strong sales in its life sciences and diagnostics units

Reports Q4 adj. profit of $1.42 per share vs estimates of $1.37 per share

Stock had risen 2.1% in 2024